Streptococcus pneumoniae(Spn)
Background. In 2012 the 13-valent conjugated pneumococcal vaccine (PCV-13) was introduced in the National Immunization Program. We performed an epidemiological study to describe SPN nasopharyngeal carriage prevalence.
Methods. Between June to September 2015 it was performed a cross-sectional study among children <3 years old, attending day care centers. Nasopharyngeal samples were collected from children at public and private centers from 5 cities of Argentina (Salta (North West), Trelew (South), Rosario (Centre), Buenos Aires (Capital city) and Posadas (North East)). Samples were analyzed at references hospitals of each city and isolates were submitted to the INEI "Dr. Carlos G. Malbrán ", for confirming and serotyping. We considered completed schedule 3 doses of PCV13, administrated14 days prior to enrollment.
Results. We included 359 toddlers, 61,6% (IC95% 56,3-66,6) were SPN carriers. Median age was 24 months, without significative difference in carriage status. Multivariate analysis showed that independently of age, sex and socioeconomic level, variables associated with carriage were:
· City: Taking Salta as reference (less carriage prevalence), Rosario and Posadas were statistically associated with higher prevalence rates: OR: 3,1 (IC95% 1,3-7,1) y OR: 2,8 (IC96% 1,2-6,3) respectively · Children attending to public day care centers had higher carriage rates than those attending private ones: OR: 1,9 (IC95% 1,06-3,4) · Children sharing bedroom with 3 or more persons, were associated to mayor risk or carriage: OR: 1,7 (IC95% 1,03-2,7)
We found 46 serotypes in the 221 isolates. (2 couldn't be serotyped), 90,9% (IC95% 86,3-94,3) were non PCV 13 serotypes (most frequent were 15B, 23B and 11A). Only 7 of 46 were PCV13 serotypes. (Graphic 1)
Of the 20 toddlers with PCV13 serotypes, 16 were completely vaccinated
Conclusion. Nasopharyngeal carriage of SPN was high in children < 3 years old attending day care centers. Most isolates were Non PCV13 serotypes. The independent predictors for higher prevalence rates were: 1-Children living in the north east and Centre of the country. 2-Those attending public day care centers and 3-Those with 3 or more persons per room.
Disclosures. All authors: No reported disclosures. X-rays were recorded from children < 5 years old with pneumonia and pleural effusion. A pediatrician and a radiologist interpreted the images independently. A second reference radiologist arbitrated when discordances occurred. Bacterial etiology was investigated in blood and/or in pleural fluid. Probably bacterial pneumonia (PBP) was determined following WHO protocol. Results were compared with previous data (2002) (2003) (2004) (2005) from the pre-PCV-13 vaccination era. Variables associated to consolidated pneumonia were evaluated by multivariate analysis using logistic regression Results. 330 patients under 5 years old with pneumonia were assisted during the study period. Of these, 92 (27.9%-IC95% 23.2-33.1) were classified as PBP. Annual incidence rate, in pre and post vaccination period and impact of vaccination are described in table 1. Incidence of pneumococcal disease could not be estimated as pneumococcal isolation was negative in all cases.
Community Acquired Pneumonia Incidence Among Children Under
Multivariate analysis of post-PCV-13 vaccination era showed that incidence of consolidated pneumonia was significantly higher in hospitalized toddlers than outpatients OR: 2,97 (1,65-5,38). Conclusion. A significant decline in consolidated pneumonia and pleural effusion incidence in <5 year old children was evidenced in Concordia after the introduction of PCV13 into national immunization program.
Disclosures. Background. Trends in distribution of S. pneumoniae capsular serotypes are associated with the introduction of pneumococcal conjugate vaccines (PCV) among population. In Colombia, 10-valent PCV (PCV10) has been included in the national vaccination program since 2011. As a part of the pneumococcal surveillance network (SIREVA), Colombia has gathered data of serotype distribution since 1993. The aim of this work is to determine the effect of PCV10 introduction on non-coverage serotypes by PCV10 in Colombia, specifically, the effect on 6A, 19A and 3 serotypes.
Methods. Information was obtained from the national surveillance program since 1993 to 2016 in children under 5 years. The isolates came from sterile sites (blood, cerebrospinal fluid, pleural fluid, articular and peritoneal fluids). All the isolates were serotyping by National Institute of Health. An interrupted time series analysis was performed to determine the effect of the PCV10 introduction on the 6A, 19A and 3 serotypes (ARIMA model).
Results. Serotyping was performed in 4683 isolates. The annual proportion trend of the 6A, 19A and 3 serotypes remained constant until 2012. An increase of double in the serotype proportion trends was observed after 2012 ( Figure) . The interrupted time-series analysis showed a positive effect of the PCV10 introduction on trends of 19A and 3 serotypes, with coefficients 20.92 (P = 0.00, ARIMA(2,0,1)) and 6.32 (P = 0.00, ARIMA(2,1,1), respectively. There was no significant effect on 6A serotype trend.
Conclusion. The introduction of PCV10 in the national vaccination program in Colombia, affected the distribution of PVC 13 capsular types non included in the PCV 7 and PCV 10 in children under 5 years. This information emphasizes the importance to surveillance the changes in serotype distributions to guide prevention strategies in children under 5 years in Colombia. Figure. 1 Trends in distribution of serotypes 19A, 3 and 6A in children under 5 years. Colombia.
Disclosures. All authors:
No reported disclosures. Background. PCV13 replaced 7-valent pneumococcal conjugate vaccine in the routine infant immunization schedule in Mexico since 2011. The use of PCV13 has reduced pneumococcal disease incidence for vaccine serotypes, particularly 19A, which emerged following PCV7 use. The 10-valent vaccine (PCV10) contains the same serotypes as PCV13 with the exception of serotypes 3, 19A and 6A but also has different conjugated proteins for the common serotypes. This study evaluated the potential health and economic implications of switching from PCV13 to PCV10 in Mexico.
Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
Methods. A decision-analytic model was developed to estimate public health and economic impact of maintaining PCV13 compared with switching to PCV10 in Mexico. Disease incidence at time of potential switch for invasive pneumococcal disease (IPD), pneumonia (PNE) and acute otitis media (AOM) was obtained from Dirección General de Epidemiología and the published literature. Historical data was used to estimate IPD trends under different infant vaccine pressures and the model forecasted disease across the population. For each vaccination program, health outcomes and associated health-care costs were estimated. Costs, utility weights, and risk of disease-specific complications were derived from published sources.
Results. In the base case, continued use of PCV13 would result in significantly fewer cases of pneumococcal disease than switching to PCV10 in Mexico (See Table 1 ). Despite a higher vaccine cost, PCV13 was cost-saving compared with PCV10 in the base case and across a number of scenarios evaluated. Costs are presented in MXN Conclusion. Continued use of PCV13 in Mexico is predicted to provide greater public health benefit compared with switching to PCV10 not only economically but also socially. It is important that policy makers consider potential implications of disease re-emergence of non-covered serotypes when considering modifications to vaccination strategies.
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